Could a daily pill lower breast cancer risk by reducing breast density?
NCT ID NCT05068388
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an oral drug called (Z)-endoxifen in 240 premenopausal women with high breast density, a known risk factor for breast cancer. Over six months, researchers measured changes in breast density using mammogram software. The goal was to see if the drug could safely reduce density compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- (Z)-endoxifen
- What this could lead to
- If successful, this could lead to a non-surgical option to reduce breast density and potentially lower breast cancer risk in premenopausal women.
- What could go wrong
- This is a phase 2 study with 240 participants, so results are still early. The drug may not significantly reduce density or could cause side effects like hot flashes or blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST DENSITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karma Study Centre
Stockholm, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.